Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1095-1102

  Devine, Steven M ^a   Flomenberg, Neal ^a   Vesole, David H ^a   Liesveld, Jane ^a   Weisdorf, Daniel ^a   Badel, Karin ^a   Calandra, Gary ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4; CD34 ANTIGEN; HETEROCYCLIC COMPOUND;

ARTICLE; BLOOD; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEUKOCYTE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION; ADULT; AGED; DRUG ANTAGONISM; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; AGED; ANTIGENS, CD34; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTORS, CXCR4; STATISTICS, NONPARAMETRIC;

EID: 1842509856     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.131     Document Type: Article

References (61)

1. Beyer J, Schwella N, Zingsem J. et al: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
2. Hartmann O, Le Corroller AG, Biaise D. et al: Peripheral blood stem-cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 126:600-607, 1997
3. Smith TJ, Hillner BE, Schmitz N, et al: Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 15:5-10, 1997
4. To LB, Haylock DN, Simmons PJ, et al: The Biology and Clinical Uses of Blood Stem Cells. Blood 89:2233-2258, 1997
5. Vose JM, Sharp G, Chan WC, et al: Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease. J Clin Oncol 20:2344-2352, 2002
6. Tricot G, Jagannath S, Vesole D, et al: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995
7. Passos-Coelho JL, Braine HG, Davis JM, et al: Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 13:705-714, 1995
8. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969, 1995
9. Glaspy JA, Shpall EJ, LeMaistre CF, et al: Peripheral Blood Progenitor Cell Mobilization Using Stem Cell Factor in Combination With Filgrastim in Breast Cancer Patients. Blood 90:2939-2951, 1997
10. Desikan KR, Barlogie B, Jagannath S, et al: Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547-1553, 1993
11. Narayanasami U, Kanteti R, Morelli J, et al: Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98:2059-2064, 2001
12. Huhn RD, Yurkow EJ, Tushinski R, et al: Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 24:839-847, 1996
13. Spitzer G, Adkins D, Mathews M, et al: Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 20:921-930, 1997
14. Molineux G, McCrea C, Van XQ. et al: Flt-3 Ligand Synergizes With Granulocyte Colony-Stimulating Factor to Increase Neutrophil Numbers and to Mobilize Peripheral Blood Stem Cells With Long-Term Repopulating Potential. Blood 89:3998-4004, 1997
15. Moskowitz CH, Stiff P, Gordon MS, et al: Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients-Results of a Phase I/II Trial. Blood 89:313-3147, 1997
16. DiPersio JF, Schuster MW, Abboud CN, et al: Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma. J Clin Oncol 18:2762-2771, 2000
17. Weaver CH, Schulman KA, Wilson-Relyea B. et al: Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18:45-53, 2000
18. Lapidot T, Petit I: Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30:973-981, 2002
19. Kollet O, Petit I, Kahn J, et al: Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation. Blood 100: 2778-2786, 2002
20. Petit I, Szyper-Kravitz M, Nagler A, et al: G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687-694, 2002
21. Levesque JP, Hendy J, Takamatsu Y. et al: Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187-196, 2003
22. Papayannopoulou T, Priestley GV, Bonig H, et al: The role of G-protein signaling in hemopoietic stem/progenitor cell mobilization. Blood 101:473-4747, 2003
23. Luster AD: Chemokines-Chemotactic Cytokines That Mediate Inflammation. N Engl J Med 338:436-445, 1998
24. Zou YR, Kottmann AH, Kuroda M, et al: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595-599, 1998
25. Tachibana K, Hirota S, Iizasa H, et al: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591-594, 1998
26. Ma Q, Jones D, Borghesani PR, et al: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A 95:9448-9453, 1998
27. Lapidot T: Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci 938:83-95, 2001
28. Peled A, Petit I, Kollet O, et al: Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283:845-848, 1999
29. Hattori K, Heissig B, Tashiro K. et al: Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97:3354-3360, 2001
30. Moore MA, Hattori K, Heissig B. et al: Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 938:35-45; discussion 45-47, 2001
31. Sweeney EA, Lortat-Jacob H, Priestley GV, et al: Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: Involvement in mobilization of stem/progenitor cells. Blood 99:44-51, 2002
32. Sweeney EA, Papayannopoulou T: Increase in circulating SDF-1 after treatment with sulfated glycans: The role of SDF-1 in mobilization. Ann N Y Acad Sci 938:48-52; discussion 52-53, 2001
33. Shen H, Cheng T, Olszak I, et al: CXCFM Desensitization Is Associated with Tissue Localization of Hemopoietic Progenitor Cells. J Immunol 166:5027-5033, 2001
34. Lapidot T, Kollet O: The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16:1992-2003, 2002
35. Yi Y, Isaacs SN, Williams DA, et al: Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: Two distinct mechanisms of HIV-1 dual tropism. J Virol 73:7117-7125, 1999
36. Donzella GA, Schols D, Lin SW, et al: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77, 1998
37. Egberink HF, De Clercq E, Van Vliet AL, et al: Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 73:6346-6352, 1999
38. Labrosse B, Brelot A, Heveker N, et al: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381-6388, 1998
39. Schols D, Este JA, Henson G, et al: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 35:147-156, 1997
40. Schols D, Struyf S, Van Damme J, et al: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388, 1997
41. Schols D, Este JA, Cabrera C, et al: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 72:4032-4037, 1998
42. Matthys P, Hatse S, Vermeire K, et al: AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 167:4686-4692, 2001
43. Hatse S, Princen K, Bridger G, et al: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527:255-262, 2002
44. Gerlach LO, Skerlj RT, Bridger GJ, et al: Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276:14153-14160, 2001
45. De Clercq E, Schols D: Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother 1:19-31, 2001 (suppl 12)
46. Hendrix CW, Flexner C, MacFarland RT, et al: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673, 2000
47. Broxmeyer HE, Hangoc G, Cooper S, et al: Interference of the SDF-1/CXCR4 axis in mice with AMD3100 induces rapid high level mobilization of hematopoietic progenitor cells, and AMD3100 acts synergistically with G-CSF and MIP-1 alpha to mobilize progenitors. Blood 98: 811a, 2001
48. Broxmeyer HE, Hangoc G, Cooper S, et al: AMD3100, an antagonist of CXCR4 and mobilizer of myeloid progenitor cells, is a potent mobilizer of competitive repopulating long term marrow self renewing stem cells in mice. Blood 100:609a, 2002
49. Liles WC, Broxmeyer HE, Rodger E, et al: Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728-2730, 2003
50. Liles WC, Rodger E, Broxmeyer HE, et al: Mobilization and collection of CD34+ progenitor cells from normal human volunteers with AMD-3100, a CXCR4 antagonist, and G-CSF. Blood 100:109a, 2002
51. Owens MA, Loken MR: Peripheral blood stem cell quantitation. Flow Cytometric Principles for Clinical Laboratory Practice. New York, Wiley-Liss, 1995, pp 111-127
52. Liles WC, Broxmeyer HE, Rodger E, et al: Leucocytosis and mobilization of pluripotent hematopoietic progenitor cells in healthy volunteers induced by single dose administration of AMD-3100, a CXCR4 antagonist. Blood 98:737a, 2001
53. Papadopoulos KP, Ayello J, Tugulea S, et al: Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61-68, 1997
54. Moskowitz CH, Classman JR, Wuest D, et al: Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 4:311-316, 1998
55. Sezer O, Possinger K, Metzner B, et al: Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. J Clin Oncol 18:3319-3320, 2000
56. Siena S, Schiavo R, Pedrazzoli P, et al: Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. J Clin Oncol 18:1360-1377, 2000
57. Laterveer L, Lindley IJ, Hamilton MS, et al: Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 85:2269-2275, 1995
58. King AG, Horowitz D, Dillon SB, et al: Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRO{beta}. Blood 97:1534-1542, 2001
59. Korbling M, Anderlini P: Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 98:2900-2908, 2001
60. Fortanier C, Kuentz M, Sutton L, et al: Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: Results of a randomised study. Bone Marrow Transplant 29:145-149, 2002
61. Rowley SD, Donaldson G, Lilleby K, et al: Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97:2541-2548, 2001